Estrigenix Therapeutics: Awarded $300,000 Grant from the National Institutes of Health

Contact:

Raquel Lamal

Red Shoes Inc.

(920) 574-3253

[email protected]

Grant supports Estrigenix’s research on new hormone replacement therapies that decrease chances of dementia in post-menopausal women

MILWAUKEE (Oct. 17, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, has been awarded a $300,000 National Institute of Health (NIH) Small Business Innovation Research (SBIR) Phase I grant. The one-year grant provides funds to support pre-clinical studies on one of Estrigenix’s lead compounds to reduce women’s suffering from the symptoms of menopause and lessen chances for dementia later in a woman’s life.

“This grant from NIH is an important milestone in Estrigenix’s commitment to developing safe and effective treatments that address the negative symptoms experienced by menopausal women without exposing them to increased risks associated with traditional hormone replacement therapy,” explained William Donaldson, Ph.D., chief executive officer (CEO) and co-founder of Estrigenix. “It’s exciting to see our research acknowledged and validated by such a renowned national organization that is committed to our efforts in helping women as they age.”

Studies have shown that as women age, they experience a decrease in estrogen production which can contribute to menopausal symptoms such as hot flashes, sleep disruption, memory dysfunction, anxiety and depression. Many traditional hormone replacement therapies (HRT) address those symptoms, but also come with associated risks for breast cancer and blood clots that can lead to a stroke. Due to these risks, some women avoid taking estrogen all together and suffer through these symptoms.

There are two estrogen receptors, ER alpha and ER beta, in the human body, and estrogen (the main component of HRT) is equally potent in activating these receptors to cause their downstream effects. ER beta is known to control vasomotor symptoms while ER alpha is associated with the proliferations of 80 percent of breast cancer cell lines. Therefore, compounds which are highly selective at activating ER beta (compared to activating ER alpha) have the potential to be safe alternatives to traditional HRT. Estrigenix is working on ER beta agonists to provide menopausal women everywhere with a potentially safer alternative to traditional HRT. The research Estrigenix has conducted, shows that if hot flashes can be reduced, then the risk of dementia in women may also be reduced later in life.

To learn more about Estrigenix and how this new therapy is helping women improve their quality of life, visit estrigenix.com.

###

About Estrigenix Therapeutics, Inc.

Estrigenix Therapeutics, Inc. is a Wisconsin-based, privately held pharmaceutical company leading the way in research and progress in estrogen biology. There is a known correlation between the severity of a woman’s hot flashes and her increased risk of developing dementia later in life. Estrigenix was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in post-menopausal women with fewer side effects than current hormone replacement therapy.

For more information and to learn how Estrigenix is pioneering the way in dementia prevention for post-menopausal women, visit estrigenix.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied and express statements regarding Estrigenix Therapeutics, Inc. plans, timelines, or presumptions of results for the Company’s lead compounds or planned development and testing. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on several assumptions concerning future events and are subject to several risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our development efforts, the fluctuation of global economic conditions, the impact of current or future pandemics on our clinical development and regulatory review and approvals and on the manufacturing and prescribing of our lead compound, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our products for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Estrigenix Therapeutics is a registered trademark of Estrigenix Therapeutics, Inc.